数据
资源
版本对比
免费注册
预约演示
免费注册
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Clinical Trials Featuring 25+ companies
2023-01-25
·
BioSpace
临床3期
临床2期
临床结果
New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) --
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Clinical Trials Featuring 25+ companies| DelveInsight Methicillin-resistant Staphylococcus aureus (MRSA) is an
infection
caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus. Rising incidence of
Methicillin-resistant Staphylococcus aureus (MRSA) infections
is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). DelveInsight’s '
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline
methicillin-resistant Staphylococcusaureus infection
therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the
methicillin-resistant Staphylococcusaureus infection
pipeline domain. Key Takeaways from the
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Report DelveInsight’s
methicillin-resistant Staphylococcusaureus infection
pipeline report depicts a robust space with 25+ companies and 28+ pipeline drugs for
methicillin-resistant Staphylococcusaureus infection
treatment. Key methicillin-resistant
Staphylococcusaureus infection
companies include
Trellis Bioscience
,
LegoChem Biosciences
,
Aptorum Group
,
ContraFect
,
Crystalgenomics
,
Cellics Therapeutics
,
MicuRx
, Oxford Antibiotic Group,
Destiny Pharma
,
TSRL, Inc.
,
TAXIS Pharmaceuticals
,
Basilea Pharmaceutica
,
Helperby Therapeutics
, Akagera Medicines,
Histogen
,
Alphamab Co. Ltd
,
Biocidium Pharmaceuticals
, and others are evaluating novel
methicillin-resistant Staphylococcusaureus infection
drugs candidate to improve the treatment landscape. Promising
methicillin-resistant Staphylococcusaureus infection
pipeline therapies in various stages of development include
TRL1068
,
Delpazolid
, ALS 4,
Teicoplanin
inhalation,
CG 400549
, SAAP 148, Exebacase, Marinus, CTI 005,
Iclaprim
, MRX 4, MRX 7, XF-73,
TXA709
,
ARV-1801
,
ACX-375C
,
ABX-605
,
IBT-V02
,
BCM-0184
,
Contezolid
, TetramOX,
Ceftobiprole
,
HY-004B8b
,
HY-005B8a
,
CG-549
,
Emricasan
,
KN043
, and several others.
Ceftobiprole
medocaril, the prodrug of the active moiety
ceftobiprole
, is a
cephalosporin antibiotic
for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. In October 2022,
Basilea Pharmaceutica
announced the results from Phase III ERADICATE study, evaluating
ceftobiprole
in the treatment of adult patients with
bacterial bloodstream infections
caused by Staphylococcus aureus. Results for the primary efficacy outcomes were consistent in key subgroups including in patients with
MSSA or MRSA bloodstream infections
at baseline, and in various categories of underlying conditions such as
skin and skin structure infections
,
abdominal abscesses
,
chronic dialysis
,
septic arthritis
,
osteomyelitis
, definite
right-sided infective endocarditis
and in patients with
persistent SAB
.
Basilea
also planned to submit a New Drug Application (NDA) for
ceftobiprole
to the
US Food and Drug Administration (FDA)
around year-end 2022.
Exebacase (CF-301)
being developed by
ContraFect Corporation
is a lysin with potent activity against Staphylococcus aureus ("Staph aureus").
Exebacase
has the potential to be the first-in-class of a new treatment for patients with
Staph aureus bacteremia
. The FDA has granted Breakthrough Therapy designation to
exebacase
for the treatment of
MRSA bloodstream infections (bacteremia)
, including
right-sided endocarditis
, when used in addition to SOC antistaphylococcal antibiotics in adult patients, based on the final data from the Phase II superiority trial of
exebacase
. In July 2022,
Destiny Pharma plc
announced that it had received an award from the Cystic Fibrosis Foundation. The research project will establish the potential of the Company’s proprietary
XF-73
drug as a novel treatment for
cystic fibrosis
patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
CTI-005
is for the treatment of Methicillin Resistance Staphylococcus Aureus (MRSA)
Pneumonia
and has been granted IND allowance from the
US FDA
. The potent
RBC-NS
has the membrane lipids and receptors that a normal red blood cell has, however, the high surface-volume ratio of the
RBC-NS
allows it to act as a decoy. This characteristic allows the RBC-NS to bind and neutralize toxins, auto-antibodies, and
bacterial infections
. The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS. Request a sample and discover the recent advances in
methicillin-resistant Staphylococcusaureus infection
treatment drugs @
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Report The
methicillin-resistant Staphylococcusaureus infection
pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage
methicillin-resistant Staphylococcusaureus infection
products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the
methicillin-resistant Staphylococcusaureus infection
pipeline landscape.
Methicillin-Resistant Staphylococcus aureus Infection
Overview Methicillin-resistant Staphylococcus aureus
(MRSA) infections
are caused by bacteria that have attained resistance from several antibiotics that treat diseases caused by Staphylococcus bacteria. The common patients of
Methicillin-resistant Staphylococcus aureus (MRSA) infections
are patients that have been in hospitals or healthcare settings for a long duration where the bacteria is found commonly.
MRSA infections
are known as healthcare-associated MRSA (HA-MRSA) if infected in hospitals. Such
infections
can spread to healthcare workers through invasive procedures, which are further transmitted to several patients by touching and operating with bare hands. Other
MRSA infections
occur in a considerable population of healthy people. People associated with community-associated MRSA (CA-MRSA) show symptoms appearing as painful skin boils. It further spreads through physical contact between individuals. The population at higher risk includes people surrounded by a significant number of people and childcare workers.
MRSA infections
might look like red bumps, pimples, or
spider bites
, accompanied by
pus
and
fever
. Find out more about
methicillin-resistant Staphylococcusaureus infection
treatment drugs @ Drugs for
Methicillin-Resistant Staphylococcus aureus Infection
Treatment A snapshot of the
Methicillin-Resistant Staphylococcus aureus Infection
pipeline drugs mentioned in the report: Drug Company Phase MoA RoA
Ceftobiprole
Basilea Pharmaceutica
Phase III Cell wall inhibitors; Peptidyltransferase inhibitors Intravenous CG 549
CrystalGenomics
Phase II Enoyl-ACP reductase inhibitors;
Fatty acid synthase
expression inhibitors;
Fatty acid synthetase
complex inhibitors Oral
BCM-0184
Biocidium Pharmaceuticals
Phase I NA Oral/Topical
TRL1068
Trellis Bioscience
Phase I Bacterial biofilm inhibitors Intravenous ALS 4
Aptorum Group
Phase I Bacterial virulence inhibitors Oral
EVX-B1
Evaxion Biotech
Preclinical Immunostimulants NA
Emricasan
Histogen
Preclinical Apoptosis inhibitors;
Caspase inhibitors
Caspase
inhibitors NA TarO inhibitor
Prokaryotics
Discovery Cell membrane inhibitors; Cell wall inhibitors NA Learn more about the emerging
methicillin-resistant Staphylococcusaureus infection
pipeline therapies @ Methicillin-Resistant Staphylococcus aureus
Infection
Clinical Trials
Methicillin-Resistant Staphylococcus aureus Infection
Therapeutics
Assessment The
methicillin-resistant Staphylococcus aureus infection
pipeline report proffers an integral view of
methicillin-resistant Staphylococcusaureus infection
emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III
Therapeutics
AssessmentBy Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical.
Therapeutics
AssessmentBy Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics
AssessmentBy Mechanism of Action: Cell wall inhibitors; Peptidyltransferase inhibitors, Enoyl-ACP reductase inhibitors;
Fatty acid synthase
expression inhibitors; Fatty acid synthetase complex inhibitors, Bacterial biofilm inhibitors, Bacterial virulence inhibitors, Immunostimulants, Apoptosis inhibitors; Caspase inhibitors, Cell membrane inhibitors; Cell wall inhibitors Key
Methicillin-Resistant Staphylococcus aureus Infection
Companies:
Trellis Bioscience
,
LegoChem Biosciences
,
Aptorum Group
,
ContraFect
,
Crystalgenomics
,
Cellics Therapeutics
,
MicuRx
, Oxford Antibiotic Group,
Destiny Pharma
,
TSRL, Inc.
,
TAXIS Pharmaceuticals
,
Basilea Pharmaceutica
,
Helperby Therapeutics
, Akagera Medicines,
Histogen
,
Alphamab Co. Ltd
,
Biocidium Pharmaceuticals
, and others. Key Methicillin-Resistant Staphylococcus aureus
Infection
Pipeline Therapies:
TRL1068
,
Delpazolid
, ALS 4,
Teicoplanin
inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005,
Iclaprim
, MRX 4, MRX 7, XF-73, TXA709,
ARV-1801
,
ACX-375C
,
ABX-605
,
IBT-V02
,
BCM-0184
,
Contezolid
, TetramOX,
Ceftobiprole
,
HY-004B8b
,
HY-005B8a
,
CG-549
,
Emricasan
,
KN043
, and others. Dive deep into rich insights for new drugs for
methicillin-resistant Staphylococcusaureus infection
treatment; visit @
Methicillin-Resistant Staphylococcus aureus Infection
Drugs Table of Contents 1.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Report Introduction 2. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Executive Summary 3.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Therapeutics 6.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline: Late Stage Products (Pre-registration) 7.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline: Late Stage Products (Phase III) 7.1
Ceftobiprole
:
Basilea Pharmaceutica
8.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline: Mid Stage Products (Phase II) 8.1 CG549:
CrystalGenomics
9.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline: Early Stage Products (Phase I) 9.1
TRL1068
:
Trellis Bioscience
10.
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline Therapeutics Assessment 11. Inactive Products in the
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the
Methicillin-Resistant Staphylococcus aureus Infection
Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the
methicillin-resistant Staphylococcusaureus infection
pipeline therapeutics, reach out @
Methicillin-Resistant Staphylococcus aureus Infection
Treatment Drugs Related Reports Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the methicillin-resistant Staphylococcusaureus epidemiology trends. Methicillin-Resistant Staphylococcus aureus Infection Market Methicillin-Resistant Staphylococcus aureus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key
methicillin-resistant Staphylococcusaureus infection
companies, including
Trellis Bioscience
,
LegoChem Biosciences
,
Aptorum Group
,
Allergan
,
iNtRON Biotechnology
,
Neupharma
,
ImmuPharma
,
Lytix Biopharma
,
CrystalGenomics
,
AIMM Therapeutics
, among others.
Staphylococcus aureus Bacteremia
Pipeline
Staphylococcus aureus Bacteremia
Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key
Staphylococcus aureus Bacteremia
companies, including
ContraFect
,
Armata Pharmaceuticals
,
iNtRON Biotechnology
,
Durata Therapeutics
,
Cipher Pharmaceuticals
,
XBiotech
,
Basilea Pharmaceutica
,
Genentech
, among others. Hospital Acquired
Methicillin-Resistant Staphylococcus aureus Infections
Pipeline Hospital Acquired
Methicillin-Resistant Staphylococcus aureus Infections
Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Hospital Acquired
Methicillin-Resistant Staphylococcus aureus Infections
companies, including
Trellis Bioscience
,
LegoChem Biosciences
,
Aptorum Group
,
Allergan
,
iNtRON Biotechnology
,
Neupharma
,
ImmuPharma
,
Lytix Biopharma
,
CrystalGenomics
,
AIMM Therapeutics
, among others. Other Trending Reports Treatment Resistant Depression Market |
Advanced Renal Cell Carcinoma
Market |
Brain Cancer
Market |
Centronuclear Myopathy
Market | Head And Neck
Squamous Cell Carcinoma
Market |
Acquired Immunodeficiency Syndrome
Market |
Acute Intermittent Porphyria
Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market |
Acute Ischemic Stroke
Ais Market |
Adenoid Cystic Carcinoma
Market | Aspergillosis Market | Biliary Atresia Market |
Biliary Tumor
Market | Chronic Inducible Urticaria Market |
Chronic Insomnia
Market |
Critical Limb Ischemia
Market | Endometriosis Pain Market |
Generalized Anxiety Disorder
Gad Market | Hallux Valgus Market | Hemophilia B Market |
Immunologic Deficiency Syndrome
Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market |
Pemphigus Vulgaris
Market | Progressive Familial
Intrahepatic Cholestasis
Market | Pruritus Market | Radiation Toxicity Market |
Pulmonary Hypertension
Associated With
Interstitial Lung Disease
Market |
Cluster Headaches
Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market |
Bile Duct Neoplasm
Market | Blood Glucose Monitoring Systems Market |
Rett Syndrome
Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare |
Hepatorenal Syndrome
Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic
Steatohepatitis
Market |
Necrotizing Enterocolitis
Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market |
Polypoidal Choroidal Vasculopathy
Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market |
Angioedema
Market |
Bladder Cancer
Market Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us atLinkedIn Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Cipher Pharmaceuticals, Inc.
Aptorum Group Ltd.
LigaChem Biosciences, Inc.
[+29]
适应症
耐甲氧西林金黄色葡萄球菌感染
感染
葡萄球菌感染
[+42]
靶点
FASN
CASP
药物
Calpurbatug
Delpazolid
替考拉宁
[+21]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务